Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.38 |
| ▸ | IDE | P14735 | 4/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605467 | 0.92 | PPARG (0.47) | PPARGPPARDPPARAPLA2G4ARORC | |
| SCHEMBL5660649 | 0.90 | PPARG (0.42) | PPARGPPARDPPARAPLA2G4AIDE | |
| SCHEMBL4606637 | 0.90 | RORC (0.45) | PPARGPPARDPPARAPLA2G4ARORC | |
| SCHEMBL4605403 | 0.90 | PPARG (0.43) | PPARGPPARDPPARAPLA2G4AIDE | |
| SCHEMBL4606980 | 0.90 | PPARG (0.45) | PPARGPPARDPPARAPLA2G4AIDE | |
| SCHEMBL4605451 | 0.89 | PPARG (0.44) | PPARGPPARDPPARAPLA2G4ARORC | |
| SCHEMBL4619831 | 0.89 | PPARG (0.44) | PPARGPPARDPPARAPLA2G4AIDE | |
| SCHEMBL4620612 | 0.87 | PPARG (0.44) | PPARGPPARDPPARAPLA2G4ARORC | |
| SCHEMBL4606690 | 0.87 | PPARG (0.44) | PPARGPPARDPPARAPLA2G4ARORC | |
| SCHEMBL4606179 | 0.86 | PPARG (0.44) | PPARGPPARDPPARAPLA2G4ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943245-A2 | 1,3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| WO-2007030559-A2 | 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PPARG, PPARA, PPARD | PPARG 1/4885PPARD 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.